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INTRODUCTION
Invasive fungal infections play a key role in contributing
to morbidity and mortality in hospitalized patients, especial-
ly those who are profoundly immunocompromised such as
patients on bone marrow transplantation (BMT). Although
a variety of yeasts and molds can cause invasive fungal infec-
tions, Candida and Aspergillus species account for the majori-
ty of the infections. Recently, other less common fungal iso-
lates, such as Zygomycetes, are recognized as opportunistic
pathogens with a increasing frequency (1, 2).
Mucormycosis is an opportunistic infection caused by fungi
of the order Mucorals, class Zygomycetes. Fungal spores are
dispersed into the air from decaying material, and the portal of
entry for human infections is via the inhalation route. Zygomy-
cetes has a tendency for vascular invasion and tissue necrosis,
with resultant hemorrhage and necrotic lesions. The major
clinical diseases can be divided into five forms according to
the site of involvement: rhinocerebral, pulmonary, gastroin-
testinal, cutaneous, and disseminated mucormycosis. Dis-
seminated mucormycosis is an extremely rare condition with
high mortality rate and generally occurs in severely immu-
nocompromised patients (3-5). 
Several cases of mucormycosis were reported in Korea, in-
cluding disseminated form after chemotherapy in a patient
with acute lymphocytic leukemia (6). Now, we first report
two cases of disseminated mucormycosis following BMT in
Korea. One was successfully treated with combination of sur-
gery, conventional and liposomal amphotericin B with dis-
continuing immunosuppressants and the other died despite
surgery and amphotericin B. In the latter patient, immuno-
suppressants could not be discontinued due to extensive graft-
versus-host disease (GVHD).
CASE REPORTS
CASE 1
A 35-yr-old man was admitted through emergency room
due to sudden development of high fever and left flank pain.
Thirteen months before he had been diagnosed as acute my-
elogenous leukemia (M5), and had received allogeneic BMT
five months after the diagnosis. He was suffering from steroid-
induced diabetes and was on combined immunosuppressive
therapy with prednisolone (40 mg/day) and cyclosporine (300
mg/day) for extensive chronic GVHD. 
On physical examination, there was tenderness on the left
costovertebral angle with hepatosplenomegaly. At this time
the leukocyte count (and neutrophil count) was within nor-
mal range. Urinalysis revealed pyuria. A chest radiograph
showed focal pneumonic infiltration in the right lower lung
field. Empirical antibiotics with cefoperazone/sulbactam,
amikacin was started. Blood, sputum, and urine cultures
were repeatedly negative for fungi and bacteria. Chest and
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Two Cases of Disseminated Mucormycosis in Patients
following Allogeneic Bone Marrow Transplantation
We describe two cases of disseminated mucormycosis following allogeneic bone
marrow transplantation (BMT). Both patients were suffering from chronic graft-ver-
sus-host disease (GVHD) and treated with prolonged administration of corticos-
teroid. In both cases, the initial symptoms were high fever and left flank pain. In-
volved organs were the spleen, right kidney and the right lung in one case, and
the spleen and the brain in the other. The diagnosis was confirmed by pathology
after splenectomy. One patient, in whom the immunosuppressesants could be
discontinued, was treated with prolonged conventional and liposomal amphotericin
B and 5-fluorocytosine. The other, in whom the immunosuppressants could not
be discontinued due to extensive GVHD, was unresponsive to amphotericin B,
and eventually died from the fungal infection. Although mucormycosis, especially
the disseminated form thereof is infrequent, it should be considered in high-risk
patients because early diagnosis and timely therapy combining antifungal drug
or surgery and reduction of immunosuppression appear to improve the prognosis.
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abdomen computed tomography (CT) scan showed pseudoa-
neurysm in the spleen (Fig. 1), abscess in the right kidney,
and pneumonic infiltration in right middle lobe of the lung.
On day 6, splenectomy was performed and showed charac-
teristically broad, irregular, and non-septate hyphae. Cyclos-
porine therapy was discontinued in an attempt to restore host
defenses. Prednisolone was also tapered to physiologic dosage
without aggravation of chronic GVHD. Amphotericin B with
5-fluorocytosine (75 mg/kg/day) was started to a dose of 1 mg/
kg/day and was later replaced by liposomal amphotericin B
(4 mg/kg/day) because of deterioration of renal function. Total
accumulated dosage of amphotericin B was 6.69 g (conven-
tional amphotericin B, 0.79 g, liposomal amphotericin B,
5.9 g in 45 days). 
He was successfully treated with combination of splenec-
tomy, prolonged use of conventional and liposomal ampho-
tericin B and 5-fluorocytosine, and discontinuing of cyclo-
sporine and prednisolone. During the 1-yr period of follow-
up after antifungal therapy, he was in good health without
relapse of the infection.
CASE 2
A 39-yr-old man was admitted due to development of fever
and left flank pain. Eight months before he had been diag-
nosed as chronic phase of chronic myelogenous leukemia and
had received allogeneic BMT three months after the diagno-
sis. The post-BMT course was complicated by steroid-induced
diabetes, veno-occlusive disease, drug-induced hepatotoxicity,
and cytomegalovirus infection. Two weeks before this event,
the patient was readmitted due to extensive chronic GVHD
involving the liver and gut, which was successfully treated
with tacrolimus and prednisolone. 
On physical examination, hepatosplenomegaly was detect-
ed. Laboratory investigation showed liver failure with coagu-
lation abnormality but leukocyte count was within normal
range. Chest radiographs were normal. Cefoperazone/sulbac-
tam, amikacin, and teicoplanin were started. Cultures of
blood, sputum, and urine were all repeatedly negative. Abdo-
men CT scan showed splenic abscess with peritoneal leakage.
On day 10, splenectomy was performed and histologic exami-
nation revealed broad, irregular, and non-septate hyphae.
Splenic arterioles were thrombosed and contained the same
hyphae (Fig. 2). Amphotericin B was started to a dose of 1
mg/kg/day and was later replaced by liposomal ampho-
tericin B (4 mg/kg/day). Because chronic GVHD were ag-
gravated during the course of tapering tacrolimus and pred-
nisolone, immunosuppressants could not be tapered. 
The patient's condition progressively deteriorated with
lethargy, confusion, stiff neck, and subsequent coma (day 20).
Cerebrospinal fluid did not show any leukocytes, and cul-
tures for bacteria, fungus, and virus were all negative. The
brain magnetic resonance scan revealed a lesion in the right
occipito-parietal cerebral hemisphere (Fig. 3). The patient
died on day 23 and the death was related with disseminated
mucormycosis. He had received amphotericin B until his
Fig. 1. Abdominal CT reveals splenomegaly, and a well defined
highly enhanced lesion with non-enhanced peripheral portion
about 4×3 cm in diameter in the perihilum of the spleen, which
is most likely the intrasplenic pseudoaneurysm with peripheral
thrombi formation.
Fig. 2. Intramural thrombi and broad, non-septate, irregular hy-
phae invading blood vessels in splenic tissue (hematoxylin-eosin
staining, ×400, arrows).Disseminated Mucormycosis Following BMT 405
death (total dose, conventional amphotericin B 0.15 g, lipo-
somal amphotericin B 1.95 g in 13 days)
DISCUSSION
Mucormycosis is an uncommon filamentous mycosis which
most frequently occurs in immunocompromised patients.
Although the epidemiological data on this fungal infection
are at best scanty, it would appear that the incidence of this
complication has increased in patients with hematological
malignancies during the last decade probably due to the more
severe and prolonged post-chemotherapeutic neutropenia
caused by the use of more aggressive treatments (4). Morri-
son et al. reported on the detection of mucormycosis infection
in 0.9% during the post-BMT period (2). Several risk factors
for mucormycosis such as prolonged neutropenia, poorly
controlled diabetes, prolonged use of steroids, and impaired
immune system were usually present in the BMT recipients,
in whom the infections are likely to progress more rapidly
(7, 8). Both of our patients were not neutropenic when mu-
cormycosis developed. But they all were diabetics, using
immunosuppressants including corticosteroids, and their
immune system, such as cell-mediated immune responses,
was impaired due to chronic extensive GVHD.
The spectrum of mucormycosis seen in the BMT popula-
tion may be different from that seen in patients with diabetes
and leukemia. The classic rhinocerebral type of infection is
not common in the BMT population (2, 7). In either of our
patients, sinonasal region was not involved, suggesting that
it may not be the main port of entry. In disseminated forms,
mucor enters through the respiratory tract and invades the
lung and arrives at other sites by embolic dissemination (1).
The most common site of spread is known to be the brain,
but metastatic necrotic lesions have also been found in the
spleen, heart, and other organs. Disseminated mucormyco-
sis is usually diagnosed after the death of the patient from
the infection. Occasionally metastatic cutaneous lesions per-
mit an earlier diagnosis (3, 5). In our cases, the infection was
first detected in the spleen and cutaneous lesions were not
present. It would be reasonable to assume that other lesions
also due to mucormycosis. But the concept should be remind-
ed that more than one microorganism can simultaneously
infect such immunocompromised patients like ours (9, 10).
Although we did not perform repeated biopsies and cultures
in other sites, if there were clinical clues that suggest two or
more different infectious processes (development of new le-
sions while receiving therapy, progression of disease, or abnor-
mal presentation of fungal infections, etc), it would be essen-
tial to obtain specimens repeatedly from the affected sites.
The hallmarks of mucormycosis are vascular invasion and
tissue necrosis. Typically, the fungi appear as broad (10 to 20
m in diameter), non-septate hyphae with branches occur-
ring at right angles. We found the typical fungi in the splenic
arterioles with intramural thrombi.
Oral antifungal prophylaxes are known to be unable to
prevent mucormycosis (1, 2). Zygomycetes are resistant to
triazole and nystatin, and whether the use of intranasal, aero-
solized, or parenteral amphotericin B can play a role in pre-
venting mucormycosis is still uncertain. Both patients in
this report had received prophylactic fluconazole during the
neutropenic period during the BMT and following 3 and 4
months, respectively.
Therapy of mucormycosis consists of rapid correction of
the predisposing factors, surgical debridement of necrotic
tissue whenever feasible, antifungal therapy, and adjunctive
therapy such as hyperbaric oxygen, granulocyte colony stim-
ulating factor, and granulocyte transfusion (3, 11, 12). Both
of our patients underwent splenectomy and received conven-
tional and liposomal amphotericin B. 
The differences between the two lie in the possibility of
discontinuation of immunosuppressants, days after the BMT,
the duration of antifungal therapy, total dosage of ampho-
tericin B, and the difference of potency of immunosuppres-
sant between cyclosporine and tacrolimus (Table 1). 
In hematologic patients the most important good prog-
nositc factor is the outcome of the hematologic disease (4).
The importance of reversing underlying factors is evident in
the experience with mucormycosis. In the former of this two
cases, discontinuation of immunosuppressants, lower poten-
cy of immunosuppressants used, and longer days after BMT,
all of which may mean the more possible immune restora-
tion, were the reason for good prognosis. The prolonged use
of amphotericin B is known to be correlated with a good
Fig. 3. Magnetic resonance scan of the brain. This T2-weighted
scan shows an extensive right occipital lobe abscess with much
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prognosis (4, 7). However, one should not lose a sight of the
fact that the correlation between the high total dosage, long
duration of use of amphotericin B and the cure of patients
could be simply due to the longer survival of these patients.
In these reports, favorable prognosis might be actually due
to the longer survival of patient rather than having received
the high total dosage of amphotericin B with longer dura-
tion.
The use of lipid formulations of amphotericin B has recent-
ly been implicated for the treatment of systemic fungal infec-
tions to reduce the toxicity of conventional amphotericin B.
In a few cases, liposomal amphotericin B has been reported
to be efficacious for the treatment of mucormycosis. How-
ever, further studies are needed to assess whether these com-
pounds are truly efficacious for the treatment of this systemic
fungal infection (3, 11). 
In conclusion, careful clinical and radiologic examinations
are the key to early diagnosis of mucormycosis, especially in
the disseminated form, in immunocompromised patients.
Early histologic confirmation certainly lead to early and pro-
per treatment i.e., antifungal therapy and surgical approach.
Successful outcome is attributed to early diagnosis in con-
junction with not only surgery or antifungal therapy, but cor-
rection of risk factors such as discontinuation or tapering of
immunosuppressants.
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Sites of infection lung, spleen, kidney spleen, brain
Days after BMT* +259 +142
WBC (×10 
9/L)* 6.4 9.4
Steroid-induced Diabetes Yes Yes
Chronic GVHD grade Extensive Extensive
(skin, liver, oral mucosa) (skin, liver, gut)
Immunosuppressants
used* (mg/day)
Cyclospirine 300 -
Tacrolimus - 4
Prednisoline 40 30
Antifungal therapy (total dose in grams)
Ampho B 0.79 0.15
Lip Ampho 5.9 1.95
5-FC 112.5
Duration of antifungal         
therapy (days) 43 13
Outcome Survived at the time Death related to      
of follow-up 1 yr later Infection
Case 1 Case 2
Table 1. Characteristics of the patients with disseminated
mucormycosis after bone marrow transplantation
BMT: bone marrow transplantation; GVHD: graft-versus-host disease;
Ampho B: amphotericin B; Lip Ampho: liposomal amphotericin B, 5-
FC: 5-fluorocytosine.
*At the time of infection.